INSTINCT BIO TECHNICAL CO HOLDINGS INC. (BIOT): Financial results for H1 2026

INSTINCT BIO TECHNICAL CO HOLDINGS INC. (BIOT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Instinct Bio Returns to Profit and Grows Revenue Nearly 10% in Yen Terms in First Half of Fiscal 2026 TOKYO, October 16, 2026 -- Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT) ("BIOT" or the "Company"), a Japan-based developer, manufacturer and seller of

Event · Earnings
Original reporting
Published Oct 16, 2026, 1:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 1:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BIOT
Neutral
high confidence
Mentioned
$BIOT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$BIOTNeutralHigh
01

Why it matters

The earnings release provides the first transparent financial picture, highlighting a profit swing and revenue growth, which may set the tone for future trading.

02

Market read

First earnings for a newly listed micro‑cap; profit return could spark short‑term buying interest, but scale limits broader market relevance.

03

What to watch

The upcoming overseas initiatives slated for 2027 could materially improve future revenue but are still uncertain.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

BIOT completed its Nasdaq listing in July 2026 and is reporting its first half‑year results as a public company.

Company-level read

Ticker impact

$BIOTNeutralHigh confidence
Context

Instinct Bio Technical Company Holdings Inc. (NASDAQ:BIOT) released its unaudited H1 2026 earnings, showing a return to profit and modest revenue growth.

Expected impact

potential modest upside as profit return may attract buyers, though margin compression could limit gains

Evidence & confidence

The earnings are a primary disclosure with new numbers; the profit swing is material for a micro‑cap, but the small absolute scale limits the move.

Market effects

Signals modest growth in the niche regenerative‑medicine cosmetics sector, but margin pressure may temper sector enthusiasm.

Limited to Japanese‑focused biotech and cosmetic firms; no immediate broader regional effect.

Low global impact given the company's small size and niche market.

Counterpoint

Margin compression and low cash reserves could outweigh the profit rebound, leading to downside risk.

Key entities

  • Instinct Bio Technical Company Holdings Inc.

    Japan‑based developer of stem‑cell‑based cosmetics, listed on Nasdaq under BIOT.

  • Tomoki Nagano

    Chairman and CEO who commented on the results and upcoming initiatives.

Related articles

$BIOTMed

Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT - Instinct Bio Technical Co (NAS

Instinct Bio (BIOT) shares fell 51.46% to $1.33 Tuesday and dropped another 20.30% in after-hours to $1.06. The Nasdaq-listed biotech completed a business combination with Relativity Acquisition Corp. It entered an indicative term sheet for an equity purchase facility to sell up to $150M of common stock over three years, priced near VWAP less a discount, to fund development and working capital.

$ROSTMedAI 8/10

Ross Stores draws more bargain hunters, but higher fuel costs and softer holiday forecast weigh on stock

Ross Stores reported Q3 sales of $6.26B, up 12% YoY, with same-store sales up 8%. Net income rose to $606M ($1.91 per share), beating targets. Shares fell 2.92% as higher fuel costs and a softer holiday forecast weighed on investors. The company maintained its holiday sales growth forecast at 4-5%, down from Q3 and last year's 9%. Ross raised its full-year profit outlook to $8.75-$8.84 per share and opened 51 new stores in Q3, totaling 2,377 stores.

$HDMedAI 8/10

Home Depot Just Delivered Great News to Investors

Home Depot (HD) reported its strongest same-store sales growth since Q3 2022, with 2.2% global and U.S. growth. CFO Richard McPhail becomes CEO, while Ted Decker transitions to chairman. Revenue rose 4.9% to $43.4B, and adjusted EPS increased 3% to $3.86. The company updated its full-year guidance, expecting 4.5% sales growth and 2% EPS increase. Management highlighted strength in professional and high-ticket sales.